BridgeBio Pharma, Inc. (BBIO)
BBIO moved a median of -0.02% 30 minutes after news, and -0.03% by the close. How BBIO actually reacts to news — the realized, point-in-time move the market made, measured across 557 labeled events over the last three years with zero look-ahead.
BBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 53% | 556 |
| 30-min | -0.02% | 49% | 556 |
| 60-min | -0.07% | 47% | 556 |
| to close | -0.03% | 48% | 550 |
| Middle 50% of BBIO reactions | -0.76% to +0.74% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 557 |
Half of all BridgeBio Pharma, Inc. news events land between -0.76% and +0.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 58 | -0.36% | 45% | +0.09% |
| Rating reiterations | 143 | +0.03% | 52% | -0.42% |
| Price-target raises | 56 | -0.01% | 48% | -0.46% |
| Price-target cuts | 10 | -0.66% | 20% | -1.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how BBIO ranks against every other measured name →
That’s how BBIO usually reacts — get an email when it moves on news →Email me when BBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BBIO's baseline. Nothing else.
Recent BBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.63% | -0.95% | |
| Form 8-K BridgeBio Pharma, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | -3.46% | |
| Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records | Press release | GlobeNewswire | +0.23% | +0.61% | |
| Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 | Press release | GlobeNewswire | +0.23% | +0.61% | |
| BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day | Press release | PR Newswire | -0.04% | +0.06% | |
| BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia | Press release | GlobeNewswire | -1.30% | -1.08% | |
| BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting | Press release | GlobeNewswire | -0.27% | -0.42% | |
| BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 | Press release | GlobeNewswire | -0.27% | -0.42% | |
| BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels | Press release | GlobeNewswire | +0.49% | -1.87% | |
| BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day | Press release | GlobeNewswire | -1.30% | -1.08% | |
| Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening | Press release | GlobeNewswire | +0.36% | -5.08% | |
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.70% | -0.64% | |
| Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial | Press release | GlobeNewswire | +0.16% | +3.33% | |
| BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 | Press release | GlobeNewswire | +1.46% | -0.13% | |
| BridgeBio to Participate in September Investor Conferences | Press release | GlobeNewswire | +0.67% | -0.05% | |
| BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans | Press release | GlobeNewswire | +0.09% | +0.37% | |
| Form 8-K BridgeBio Pharma, Inc. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -0.20% | |
| Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM | Press release | GlobeNewswire | -0.22% | +0.51% | |
| BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM | Press release | GlobeNewswire | +0.60% | -0.48% | |
| BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 | Press release | GlobeNewswire | +0.71% | +0.10% | |
| Form 8-K BridgeBio Pharma, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | +0.94% | |
| BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base | Press release | GlobeNewswire | -0.28% | -0.35% | |
| BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder | Press release | GlobeNewswire | -0.28% | -0.35% | |
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.11% | +0.44% | |
| BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET | Press release | GlobeNewswire | -1.38% | +0.05% | |
| Form S-3ASR BridgeBio Pharma, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +0.76% | +0.10% | |
| Form S-8 BridgeBio Pharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.76% | +0.10% | |
| BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 | Press release | GlobeNewswire | -0.09% | +0.51% | |
| Form 8-K BridgeBio Pharma, Inc. For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +0.64% | |
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.20% | -2.07% | |
| Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM | Press release | GlobeNewswire | -0.27% | +2.92% | |
| Form 8-K BridgeBio Pharma, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +0.28% | |
| BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches | Press release | GlobeNewswire | +0.15% | +0.05% | |
| BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia | Press release | GlobeNewswire | +0.29% | +1.01% | |
| Form 8-K BridgeBio Pharma, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | +1.02% | |
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.10% | +0.16% | |
| BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026 | Press release | GlobeNewswire | +2.17% | +3.87% | |
| BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 | Press release | GlobeNewswire | -1.46% | -2.38% | |
| Form 8-K BridgeBio Pharma, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | +3.01% | |
| Form 8-K BridgeBio Pharma, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | +1.10% | |
| BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 | Press release | GlobeNewswire | -0.91% | +1.55% | |
| Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure | Press release | GlobeNewswire | -1.89% | -5.27% | |
| BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.89% | -5.27% | |
| Form 8-K BridgeBio Pharma, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +1.29% | |
| Form S-3ASR BridgeBio Pharma, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +2.12% | +1.29% | |
| BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates | Press release | GlobeNewswire | +2.12% | +1.29% | |
| Form 10-Q BridgeBio Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.12% | +1.29% | |
| Form 8-K BridgeBio Pharma, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +1.29% | |
| BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (=90%), Approved by ANVISA to Treat ATTR-CM in Brazil | Press release | GlobeNewswire | +0.64% | -0.95% | |
| BridgeBio to Participate in May and June Investor Conferences | Press release | GlobeNewswire | -0.69% | -1.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BBIO section they belong to.
Where else BBIO is measured.
BBIO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BridgeBio Pharma, Inc.'s median reaction calculated?
Every labeled BBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 557 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of BBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.